OBJECTIVE: To assess if ultrasound (US)-guided viscosupplementation can reduce pain and improve function in elderly patients with cuff tear arthropathy. PATIENTS AND METHODS: Ninety-three patients aged over 65 with grade 3 or above cuff tear arthropathy were included in this prospective open-label non-randomized trial. Institutional review board approval and informed consent were obtained. Thirty-three patients received intra-articular injections of sodium hyaluronate under US guidance. Sixty patients constituted the control group. Shoulder joint function was assessed with Constant scores (CS) and pain with a visual analogue scale (VAS). RESULTS: Compared with controls, treated patients reported a significant decrease in symptoms at 1 (mean CS 66±3.1 vs 37±6.9; mean VAS 1.9±1.2 vs 6.9±2.2), 2 (mean CS 65±3.2 vs 35±7.2; mean VAS 1.7±1.2 vs 6.8±2.5), 3 (mean CS 66±3.4 vs 33 6.1; mean VAS 2.3±1.2 vs 6.6±1.9), and 4 (mean CS 62±3.0 vs 34±6.5; mean VAS 3.3±1.4 vs 7.8±3.1) months, p<0.001. After 5 months there were no differences. CONCLUSION: US-guided viscosupplementation is a beneficial therapeutic option in the first months of treatment.
OBJECTIVE: To assess if ultrasound (US)-guided viscosupplementation can reduce pain and improve function in elderly patients with cuff tear arthropathy. PATIENTS AND METHODS: Ninety-three patients aged over 65 with grade 3 or above cuff tear arthropathy were included in this prospective open-label non-randomized trial. Institutional review board approval and informed consent were obtained. Thirty-three patients received intra-articular injections of sodium hyaluronate under US guidance. Sixty patients constituted the control group. Shoulder joint function was assessed with Constant scores (CS) and pain with a visual analogue scale (VAS). RESULTS: Compared with controls, treated patients reported a significant decrease in symptoms at 1 (mean CS 66±3.1 vs 37±6.9; mean VAS 1.9±1.2 vs 6.9±2.2), 2 (mean CS 65±3.2 vs 35±7.2; mean VAS 1.7±1.2 vs 6.8±2.5), 3 (mean CS 66±3.4 vs 33 6.1; mean VAS 2.3±1.2 vs 6.6±1.9), and 4 (mean CS 62±3.0 vs 34±6.5; mean VAS 3.3±1.4 vs 7.8±3.1) months, p<0.001. After 5 months there were no differences. CONCLUSION: US-guided viscosupplementation is a beneficial therapeutic option in the first months of treatment.
Authors: Eric Noël; Philippe Hardy; Frank-Wolfgang Hagena; Erick Laprelle; Felix Goebel; Christine Faure; Luc Favard; Pascal Gaudin; Ralph Christ; Christophe Baudot; Julia Dietl; Philippe Goupille Journal: Joint Bone Spine Date: 2009-12 Impact factor: 4.929
Authors: Jasmin Arrich; Franz Piribauer; Philipp Mad; Daniela Schmid; Klaus Klaushofer; Marcus Müllner Journal: CMAJ Date: 2005-04-12 Impact factor: 8.262
Authors: Theodore Blaine; Roland Moskowitz; James Udell; Michael Skyhar; Robert Levin; Jeffrey Friedlander; Michael Daley; Roy Altman Journal: J Bone Joint Surg Am Date: 2008-05 Impact factor: 5.284
Authors: Jonathan S Kirschner; Jennifer Cheng; Andrew Creighton; Kristen Santiago; Nicole Hurwitz; Mark Dundas; Nicholas Beatty; Dallas Kingsbury; Gabrielle Konin; Zafir Abutalib; Richard Chang Journal: Clin J Sport Med Date: 2022-03-17 Impact factor: 3.454
Authors: Alberto Tagliafico; Giuseppe Russo; Sara Boccalini; Johan Michaud; Andrea Klauser; Giovanni Serafini; Carlo Martinoli Journal: Radiol Med Date: 2013-12-03 Impact factor: 3.469
Authors: A Migliore; E Bizzi; O De Lucia; A Delle Sedie; S Tropea; M Bentivegna; A Mahmoud; C Foti Journal: Clin Med Insights Arthritis Musculoskelet Disord Date: 2016-06-07